VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

9773	Companies
195566	Keywords
126551	Articles
103964	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 02/05/2025 at 07:00, 11 months 24 days ago

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
Valneva receives marketing authorization in the UK for the world's first chikungunya vaccine, IXCHIQ®. Single-dose vaccine for individuals 18+ provides rapid and strong immune response

UK Valneva MHRA Chikungunya Vaccine IXCHIQ®
BRIEF

published on 12/05/2024 at 07:35, 1 year 1 month ago

Valneva Reports Share and Voting Rights as of November 30, 2024

Euronext Paris Share Capital Voting Rights Valneva Double Voting
PRESS RELEASE

published on 12/05/2024 at 07:30, 1 year 1 month ago

VALNEVA - Declaration of shares and voting rights: November 30, 2024
VALNEVA declares transfer of 1,000 shares into bearer form with double voting rights on November 26, 2024. Total voting rights: 178,371,727

Euronext Paris Voting Rights Shares Stock Market Valneva
BRIEF

published on 12/04/2024 at 10:02, 1 year 1 month ago

Polar Capital reduces its stake in VALNEVA SE

Voting Rights Actions Valneva SE Threshold Crossing Polar Capital
BRIEF

published on 12/04/2024 at 07:05, 1 year 1 month ago

Valneva Publishes Findings on Chikungunya Impact in British Medical Journal

Climate Change Chikungunya Health Impact Economic Burden Global Study
PRESS RELEASE

published on 12/04/2024 at 07:00, 1 year 1 month ago

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal
Valneva SE announces the publication of an article on the global health and economic burden of chikungunya in The British Medical Journal, revealing higher disease burden and substantial costs

Valneva SE Global Health Chikungunya Economic Burden British Medical Journal
BRIEF

published on 11/26/2024 at 17:50, 1 year 2 months ago

Valneva Seeks FDA Approval for Chikungunya Vaccine Expansion

Valneva FDA Application Chikungunya Vaccine Adolescents Antibody Persistence
PRESS RELEASE

published on 11/26/2024 at 17:45, 1 year 2 months ago

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
Valneva submits label extension application to U.S. FDA for its chikungunya vaccine, IXCHIQ®, to potentially include adolescents aged 12 to 17 years and two-year antibody persistence data

FDA Valneva Chikungunya Vaccine IXCHIQ Label Extension Application
BRIEF

published on 10/10/2024 at 07:05, 1 year 3 months ago

Valneva presents its outlook at an investor day in New York

Investors Growth Valneva Vaccines Lyme
PRESS RELEASE

published on 10/10/2024 at 07:00, 1 year 3 months ago

Valneva Hosts Investor Day in New York City
Valneva SE is hosting an investor day in New York City to discuss key value drivers, including Lyme disease vaccine, commercial vaccines, and R&D pipeline. Hybrid event with webcast and Q&A sessions

Investor Day Valneva SE Lyme Disease Vaccine R&D Pipeline Commercial Vaccines

Accesswire

Published on 01/30/2026 at 00:00, 1 hour 2 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 2 hours 2 minutes ago

PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A
Published on 01/29/2026 at 18:45, 6 hours 17 minutes ago

Silver Spruce Appoints Vice-President of Exploration
Published on 01/29/2026 at 18:00, 7 hours 2 minutes ago

PPX Mining Announces Grant of Restricted Share Units and Deferred Share Units
Published on 01/29/2026 at 17:00, 8 hours 2 minutes ago

Sparta Reports on Delay in Filing Annual Financial Statements

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 00:07, 54 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Appointment of independent non-executive director
Published on 01/29/2026 at 21:02, 3 hours 59 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/29/2026 at 21:01, 4 hours 1 minute ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 01/29/2026 at 20:59, 4 hours 2 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited
Published on 01/29/2026 at 20:57, 4 hours 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc

Les Echos

Published on 01/29/2026 at 18:00, 7 hours 2 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 7 hours 17 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 7 hours 17 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 7 hours 22 minutes ago

ALTEN: Annual revenue 2025
Published on 01/29/2026 at 10:07, 14 hours 54 minutes ago

Deezer confirms demonetization of up to 85% of AI-music streams due to fraud and moves to sell AI-detection tech

View all LES ECHOS COMFI WIRE